Cangene signs agreement to supply the U.S. Department of Defense with VIG product
Cangene Corporation reported that the Chemical Biological Medical Systems project management Office of the United States Department of Defense ("DoD") has signed an agreement to purchase Cangene's Vaccinia Immune Globulin Intravenous (Human) ("VIG"). The four-year, sole-source base contract is valued at approximately US$4.9 million. Cangene expects to deliver the product during fiscal 2010.
The DoD has two options to purchase additional product during the course of the contract, which if exercised, could add approximately US$7 million to the total value. This contract is independent of Cangene's agreement with the U.S. Centers for Disease Control and Prevention for the supply of VIG; the DoD's stockpile of the product will be maintained for use by United States military personnel under the DoD's Smallpox Immunization Program. Cangene's VIG product was approved by the U.S. Food and Drug Administration ("FDA") in 2005.
VIG is a hyperimmune product intended for use in treating and preventing certain types of severe complications that may be associated with smallpox vaccination and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified, specialty antibodies made from plasma.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Mind Over Microbiome: How Mental States Impact Gut Health - New research reveals brain-gut circuit regulating immunity through microbiome modulation
€ 1 Million Research Grant Awarded for the First Time - Merck awarded a grant known as the Future Insight Prize for the first time
Therapy for muscular dystrophy: A new start-up - To date, there is no treatment for this life-threatening genetic disease
EHEC infections can have serious consequences for children - BfR leaflet informs about the transmission paths
Are ultra-processed foods a risk to health? - High intake of several emulsifier E numbers linked to increased cardiovascular disease risk
Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model - Pilot Study Demonstrates 50% Survival in Valortim-Treated Animals
Enzyme with high potential for new cancer treatment identified
Our versatile viral defenses - Researchers systematically track protein interactions in defense against viruses
QIAGEN achieves Personalized Healthcare milestone with U.S. approval of companion diagnostic for colorectal cancer
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Mobile gold fingers
